Siemens ups Amyvid production, distribution

| | Health Imaging | Molecular Imaging

Siemens PETNET Solutions has expanded manufacturing and distribution of the amyloid-targeting imaging agent F-18 Florbetapir (Amyvid) to 17 sites.

This increases availability of the PET tracer to eight metropolitan areas across the PETNET Solutions network, including Los Angeles, Boston, Minneapolis, Fort Lauderdale, Fla. and Cleveland. The agent is also being produced and shipped out of Raleigh, N.C., and Hackensack, N.J.

Manufacturing and distribution of the Eli Lilly radiopharmaceutical continues in Chicago, Dallas, Houston, Atlanta, Seattle, Philadelphia and St. Louis, Mo. as well as Palo Alto, Calif., And Jacksonville, Fla.

Amyvid  was approved by the FDA for PETimaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline in April 2012. Amyvid was first made available to imaging centers in markets surrounding 16 manufacturing sites in the U.S. in June 2012.

 

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.